For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Phentolamine Ophthalmic Solution 0.75% | One drop in both eyes at or near bedtime (8PM to 10PM) Phentolamine Ophthalmic Solution 0.75%: 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist | 0 | None | 0 | 71 | 23 | 71 | View |
| Phentolamine Ophthalmic Solution Vehicle | One drop in both eyes at or near bedtime (8PM to 10PM) Phentolamine Ophthalmic Solution Vehicle (Placebo): Topical sterile ophthalmic solution | 0 | None | 0 | 73 | 2 | 73 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Instillation site pain | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Dysgeusia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Conjunctival Hyperaemia | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Instillation site erythema | SYSTEMATIC_ASSESSMENT | General disorders | None | View |